Andrew Tutt

38PUBLICATIONS
305CO-AUTHORS
Molecular targetsCancer diagnosisPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Sep 22, 2026
The anion channel GPR89 is a tumor-specific dependency in breast cancer.

|Sep 21, 2026
PUM3 is an essential suppressor of replication stress in homologous recombination deficient breast cancer.

|Sep 21, 2026
Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study.

|Jul 15, 2026
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.

|May 06, 2026
Two decades of PARP inhibitor synthetic lethality in cancer.

|Apr 28, 2026
A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.

Pageof 7

Frequent Collaborators

16 joint publications

Christopher J Lord

13 joint publications

Syed Haider

12 joint publications

Anita Grigoriadis

11 joint publications

Stephen Pettitt